{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:09:09Z","timestamp":1779282549891,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,20]]},"DOI":"10.7759\/cureus.109271","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:22:46Z","timestamp":1779279766000},"source":"Crossref","is-referenced-by-count":0,"title":["Low-Positive Myelin Oligodendrocyte Glycoprotein (MOG)-Immunoglobulin G (IgG) in Pediatric Demyelinating Disease: How Imaging Features Can Support a MOG Antibody-Associated Disease (MOGAD) Diagnosis"],"prefix":"10.7759","author":[{"given":"Chun Lang","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine Wing Shan","family":"Fok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin BP","year":"2025","unstructured":"Trewin BP, Brilot F, Reddel SW, Dale RC, Ramanathan S. MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev. 2025, 24:103693. 10.1016\/j.autrev.2024.103693","journal-title":"Autoimmun Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209321","article-title":"Validation of the 2023 international diagnostic criteria for MOGAD in a selected cohort of adults and children","volume":"103","author":"Varley JA","year":"2024","unstructured":"Varley JA, Champsas D, Prossor T, et al.. Validation of the 2023 international diagnostic criteria for MOGAD in a selected cohort of adults and children. Neurology. 2024, 103:e209321. 10.1212\/WNL.0000000000209321","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251313744","article-title":"Testing for myelin oligodendrocyte glycoprotein antibodies: who, what, where, when, why, and how","volume":"31","author":"Budhram A","year":"2025","unstructured":"Budhram A, Flanagan EP. Testing for myelin oligodendrocyte glycoprotein antibodies: who, what, where, when, why, and how. Mult Scler. 2025, 31:505-11. 10.1177\/13524585251313744","journal-title":"Mult Scler"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/sclerosis4020009","article-title":"From low-positive fixed cell-based assay to confirmed myelin oligodendrocyte glycoprotein antibody-associated disease: a paediatric case report","volume":"4","author":"Santib\u00e1\u00f1ez T","year":"2026","unstructured":"Santib\u00e1\u00f1ez T, Vald\u00e9s JM, Galleguillos L. From low-positive fixed cell-based assay to confirmed myelin oligodendrocyte glycoprotein antibody-associated disease: a paediatric case report. Sclerosis. 2026, 4:9. 10.3390\/sclerosis4020009","journal-title":"Sclerosis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1137998","article-title":"Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease","volume":"14","author":"Corbali O","year":"2023","unstructured":"Corbali O, Chitnis T. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front Neurol. 2023, 14:1137998. 10.3389\/fneur.2023.1137998","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1260358","article-title":"Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide","volume":"14","author":"Hor JY","year":"2023","unstructured":"Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol. 2023, 14:1260358. 10.3389\/fneur.2023.1260358","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-024-06023-2","article-title":"Radiological features in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease-diagnostic criteria and lesion dynamics","volume":"55","author":"Pratt LT","year":"2025","unstructured":"Pratt LT, Meirson H, Shapira Rootman M, Ben-Sira L, Shiran SI. Radiological features in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease-diagnostic criteria and lesion dynamics. Pediatr Radiol. 2025, 55:699-720. 10.1007\/s00247-024-06023-2","journal-title":"Pediatr Radiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD:  how it differs from and resembles other neuroinflammatory disorders","volume":"216","author":"Shahriari M","year":"2021","unstructured":"Shahriari M, Sotirchos ES, Newsome SD, Yousem DM. MOGAD:  how it differs from and resembles other neuroinflammatory disorders. AJR Am J Roentgenol. 2021, 216:1031-9. 10.2214\/AJR.20.24061","journal-title":"AJR Am J Roentgenol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162647","article-title":"Pediatric myelin oligodendrocyte glycoprotein antibody-associated disease in southern China: analysis of 93 cases","volume":"14","author":"Li X","year":"2023","unstructured":"Li X, Wu W, Hou C, et al.. Pediatric myelin oligodendrocyte glycoprotein antibody-associated disease in southern China: analysis of 93 cases. Front Immunol. 2023, 14:1162647. 10.3389\/fimmu.2023.1162647","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi E","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022, 13:885218. 10.3389\/fneur.2022.885218","journal-title":"Front Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam DH","year":"2020","unstructured":"Whittam DH, Karthikeayan V, Gibbons E, et al.. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020, 267:3565-77. 10.1007\/s00415-020-10026-y","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-023-00776-1","article-title":"Emerging principles for treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"25","author":"Wolf AB","year":"2023","unstructured":"Wolf AB, Palace J, Bennett JL. Emerging principles for treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Curr Treat Options Neurol. 2023, 25:437-53. 10.1007\/s11940-023-00776-1","journal-title":"Curr Treat Options Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga AS","year":"2020","unstructured":"Lopez-Chiriboga AS, Sechi E, Buciuc M, Chen JJ, Pittock SJ, Lucchinetti CF, Flanagan EP. Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder. JAMA Neurol. 2020, 77:1575-7. 10.1001\/jamaneurol.2020.3115","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S372446","article-title":"Radiological features for outcomes of MOGAD in children: a cohort in southwest China","volume":"18","author":"Fan X","year":"2022","unstructured":"Fan X, Li Q, Li T, et al.. Radiological features for outcomes of MOGAD in children: a cohort in southwest China. Neuropsychiatr Dis Treat. 2022, 18:1875-84. 10.2147\/NDT.S372446","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/485663-low-positive-myelin-oligodendrocyte-glycoprotein-mog-immunoglobulin-g-igg-in-pediatric-demyelinating-disease-how-imaging-features-can-support-a-mog-antibody-associated-disease-mogad-diagnosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:22:47Z","timestamp":1779279767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/485663-low-positive-myelin-oligodendrocyte-glycoprotein-mog-immunoglobulin-g-igg-in-pediatric-demyelinating-disease-how-imaging-features-can-support-a-mog-antibody-associated-disease-mogad-diagnosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.109271","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}